Russian-made Coronavirus vaccine Sputnik, which is currently undergoing trials in India, could be available for use from March- April, Dr Reddy's Laboratories, which is manufacturing the vaccine, has said.
The efficacy of Sputnik, according to interim results from the Lancet study, was 91.6 per cent. Deepak Sapra, the chief of API and pharma services at Dr Reddy's, has told NDTV that the results of Sputnik trials on 20,000 people show that its efficacy cuts across age groups and co-morbidities.
For the 60-plus age group, the vaccine showed an efficacy of 91.8 per cent, which proves its consistency, he added.
The phase 2 trials in India for Sputnik were over in December. Data from Phase 2 trials showed "excellent safety and immunogenicity, Sapra said.
The Phase 3 trials, which are currently on, will be finished in February, after which the company will approach the drugs regulator for emergency approval.